Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Disney's stock is under renewed pressure as its core businesses face slower growth. The market is awaiting clearer pr...
Over the last decade, the iShares S&P 100 ETF led large-cap funds with outsized gains, but 2026’s early volatility hi...
Microsoft stock slid about 25% in Q1 2026, its worst showing in years, as AI spending accelerates yet revenue signals...
FuboTV has faced a brutal stretch, yet new synergies from Disney and Hulu may set up a rebound in EBITDA and subscrib...
FUTY has delivered 64% returns over five years while charging just 0.084% in fees, as the utility sector blends stead...
Vanguard Value ETF (VTV) acts as a steady core for income-focused portfolios in 2026, delivering income and defense a...
MSFW has fallen sharply since its July 2025 launch, while weekly payouts crater from a peak of $0.97 to a recent $0.1...
Money moments can feel forced and awkward—whether inflation, debt, or family pressure. This guide turns that discomfo...
Inside CPAC, Republicans cheered painted a confident scene, but poll numbers outside told a tougher truth. This artic...
When a marquee investor trims big tech bets, markets watch closely. This article explores cathie wood's invest dumps,...
Two popular ETFs, SPGM and EEM, offer global stock exposure with distinct cost and risk profiles. This guide breaks d...